COVID-19 and atrial fibrillation: Intercepting lines

Abstract

Almost 20% of COVID-19 patients have a history of atrial fibrillation (AF), but also a new-onset AF represents a frequent complication in COVID-19. Clinical evidence demonstrates that COVID-19, by promoting the evolution of a prothrombotic state, increases the susceptibility to arrhythmic events during the infective stages and presumably during post-recovery. AF itself is the most frequent form of arrhythmia and is associated with substantial morbidity and mortality. One of the molecular factors involved in COVID-19-related AF episodes is the angiotensin-converting enzyme (ACE) 2 availability. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses ACE2 to enter and infect multiple cells. Atrial ACE2 internalization after binding to SARS-CoV-2 results in a raise of angiotensin (Ang) II, and in a suppression of cardioprotective Ang(1–7) formation, and thereby promoting cardiac hypertrophy, fibrosis and oxidative stress. Furthermore, several pharmacological agents used in COVID-19 patients may have a higher risk of inducing electrophysiological changes and cardiac dysfunction. Azithromycin, lopinavir/ritonavir, ibrutinib, and remdesivir, used in the treatment of COVID-19, may predispose to an increased risk of cardiac arrhythmia. In this review, putative mechanisms involved in COVID-19-related AF episodes and the cardiovascular safety profile of drugs used for the treatment of COVID-19 are summarized.

1. Introduction

An outburst of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in December 2019, prompting Health Agencies to issue a public health emergency (1). Since then, the viral infection has reached epidemic proportions, affecting nearly 300 million people in 2 years (2). Most cases are asymptomatic or associated with mild symptoms, but a significant minority of patients develops severe symptoms that can result in multiple organ failure and death (3). Mortality rate is increased by age, pre-existing cardiovascular diseases and metabolic disorders conditions such as hypertension, heart failure, type 2 diabetes and obesity (4–6). The main extra-pulmonary site involved in COVID-19 is the cardiovascular system. Early cardiac injury, evidenced by elevated cardiac biomarkers, is associated to mortality, and has been reported in hospitalized COVID-19 patients (7).

Due to the initial lack of knowledge of COVID-19 pathophysiology and thus, effective treatments, compassionate and emergency use of drugs including numerous antibodies have been approved. During the pandemic phase, several drug classes have been used either as monotherapy or in combination to minimize disease severity (8–10; Figure 1).

FIGURE 1.

Pharmacological therapy of COVID-19. Antiviral (RNA polymerase and protease inhibitors, monoclonal antibodies), immunomodulatory (IL-1 and IL-6 antagonists, JAK inhibitors) or other drugs (antibiotics, tyrosine kinase inhibitors) are used either alone or in combination.

Cardiac manifestations related to COVID-19 infection include arrhythmias, acute myocardial infarction and myocarditis (11). While the etiology of cardiac manifestations is multifactorial, it is possible that also genetic background, such as clinically silent and previously unrecognized channelopathies, can make these patients susceptible to cardiac arrhythmias. Interestingly, atrial fibrillation (AF) and COVID-19 infection appear to share some pathophysiological features, both being driven by an immune response, with inflammatory markers, such as C-reactive protein and cytokine interleukin (IL)-6, correlating with disease severity and mortality (12–14). Therefore, it is understandable that a high incidence of AF with COVID-19 has been reported (15–17).

Although a common immunoinflammatory substrate between COVID-19 and AF has emerged, a few studies have evaluate whether the COVID-19 inflammatory mediators are uniquely responsible for AF or whether this arrhythmia is related to a non-specific product of severe viral respiratory illness.

2. The outline of AF pathophysiology

Atrial fibrillation (AF), the most common type of cardiac arrhythmia, is an evolving age-related disease where co-morbidities or lifestyle conditions, such as hypertension, diabetes mellitus, obesity, chronic kidney disease and inflammatory diseases, play a pivotal role (18, 19). In 30% of cases, however, the arrhythmia manifests in asymptomatic subjects not affected by any of the previous pathologies, significantly reducing the quality of life (20).

Atrial fibrillation (AF) pathogenesis is associated with atrial electrical and structural remodeling (21, 22). Short and long-term electrical remodeling present different substrates: the former is related to an altered intracellular Ca²⁺ level via ryanodine receptors (RyRs) and voltage-dependent L-type Ca²⁺ current inactivation, the latter is related to reduce levels of mRNA transcript encoding ion channels or to post-transcriptional mechanisms (23). From the structural viewpoint, pro-fibrotic atrial remodeling has been shown to increase the AF susceptibility, contributing to the transition from paroxysmal to persistent or permanent AF (24). Myocardial fibrosis and the activation of its molecular and cellular drivers have been observed in atrial tissue of AF patients, demonstrating also a positive correlation between the degree of atrial fibrosis and the persistence of AF (25). Of note, pharmacotherapy with anti-fibrotic potential (i.e., statins and renin-angiotensin-aldosterone system (RAAS) inhibitors) effectively limits the formation of this structural substrate of AF (26).

Further, inflammation and reactive oxygen species also contribute to unbalanced homeostasis of atrial myocardium, promoting not only the onset but also the AF duration. Inflammatory cell infiltration and increased serum levels of inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, IL-8, and IL-10, have been found in AF patients, correlating with AF duration and severity (27). Accordingly, treatments pointing at decreasing inflammatory response and oxidative stress have shown promising results by alleviating atrial structural and electrical remodeling (28).

Undoubtedly, a deeper understanding of the underlying AF pathophysiology as well as the individual patient characteristics are still needed to expand the effective and safe therapeutic armamentarium, and optimize a personalized pharmacotherapy.

2.1. AF in COVID-19 patients

Atrial fibrillation (AF) is the most common form of arrhythmia in COVID-19 patients, and can be the first sign even prior to evident respiratory distress (29). Almost 20% of COVID-19 patients have a history of AF, but also a new-onset AF represents a frequent complication in COVID-19 with a risk ranging between 10 and 18% (30–32). In a multicenter retrospective cohort study, the incidence of AF during hospitalization is 10% and the incidence of new-onset AF in patients without a pre-existing history of atrial arrhythmias is 4% (33).

Clinical evidence from hospitalized patients has demonstrated that COVID-19, by promoting the evolution toward a prothrombotic state, increases the susceptibility to AF during the infective stages and presumably during post-recovery (34). Meta-analysis studies revealed that pre-existing AF in patients with COVID-19 is associated with increased in-hospital mortality, post-discharge mortality and mechanical ventilation use (35). New-onset AF in the context of COVID-19-related pneumonia is linked to adverse prognosis, suggesting a correlation with the degree of inflammatory and hypoxemic viral insult that increase the hypercoagulable state, endothelial dysfunction, and oxidative stress (36). In general, as for all critically ill patients in which AF independently increases the risk of stroke, length of hospitalization, and death (37), this arrhythmia complicates the clinical course also in COVID-19 patients.

2.2. AF and COVID-19: Mechanistic insights

In attempt to outline a pathophysiology of COVID-19-related AF, several putative mechanisms have been proposed. They include a reduced availability of angiotensin-converting enzyme (ACE) 2, binding of viral spike protein to CD147 or sialic acid, enhancement of inflammatory signaling culminating in cytokine storm, endothelial damage and increased adrenergic drive (38; Figure 2).

FIGURE 2.

Pathophysiology of COVID-19-related atrial fibrillation (AF) events. Putative mechanisms include a reduced availability of angiotensin-converting enzyme 2, binding of viral spike protein to CD147 or sialic acid, enhancement of inflammatory signaling culminating in cytokine storm, endothelial damage, and increased adrenergic drive.

Angiotensin-converting enzyme 2 (ACE2) converts angiotensin (Ang) I and Ang II into active peptides Ang(1–9) and Ang(1–7), respectively, which provide counter-regulatory effects for the classical RAAS axis (39, 40). After the cleavage of the viral spike protein, SARS-CoV-2 uses ACE2 to enter and infect host cells such as cardiomyocytes, pericytes, pneumocytes, endothelial cells, and macrophages (41–43). This interaction results in a reduction of ACE2 on the cell surface, suppressing a key pathway for the degradation of Ang II to form cardioprotective Ang(1–7). The consequent increase in Ang II/Ang(1–7) ratio shifts the balance to Ang II thereby promoting cardiac hypertrophy, vasoconstriction, tissue fibrosis, and oxidative stress (9). Moreover, atrial ACE2 catabolizes transforming growth factor-β1 (TGF-β1), the principal pro-fibrotic cytokine (44). This may underlie atrial arrhythmogenesis and potentially increase the susceptibility to AF in COVID-19 patients (45). ACE2 is also involved in the regulation of the cardiac action potential. Ang(1–7) modulates Ca²⁺ homeostasis and cellular electrophysiology in atrial tissue and pulmonary veins (46, 47). Experimental animal studies have demonstrated an increased expression of ACE2 receptor following treatment with ACE inhibitors and angiotensin receptor blockers (48). Studies on ACE2 expression conducted in experimental models and human transcriptome to identify the organs more susceptible to this infection have revealed a low level in the lung, mainly limited to a small fraction of type II alveolar epithelial cells (49). It has been hypothesized that the massive release of inflammatory cytokines is responsible of an increase in ACE2 expression, thus potentiating the infection (50–52).

CD147 is an adjunctive player that facilitates SARS-CoV-2 invasion into host cells, including cardiomyocytes, by interacting with viral spike protein (53, 54). Although the involvement of CD147 in SARS-CoV-2 infection is still debated, it may represent a possible therapeutic target to challenge COVID-19 (55, 56). Furthermore, CD147 upregulates cytokine expression, stimulates oxidative stress in cardiomyocytes and promotes negative ionotropic effects (57). In cardiomyocytes, CD147 is a strong inducer of IL-18 that activates matrix metalloproteinases (MMPs) and circulating IL-18 levels positively correlates with AF development (58). MMP-9 increases extracellular matrix components degradation but can also activate TGF-β1, favoring myocardial adverse remodeling. Higher plasma levels of MMP-9 found in AF patients suggest that MMP-9 can be a marker of atrial remodeling (59). Interestingly, also in COVID-19 patients increased circulating MMP-9 is found (60). Although the role of this protease in tissue damage and repair at the pulmonary level remains to be clarified, the emerging picture is that the levels of MMP-9 increases during the course of the disease and correlates with the number of circulating inflammatory cells (61, 62).

The spike proteins of several coronaviruses bind to sialic acid on the cell surface (63). N-acetylneuraminic acid, the predominant sialic acid in human glycoproteins and gangliosides. By activating RhoA signaling, N-acetylneuraminic acid may trigger cardiac fibrosis and atrial enlargement, contributing to AF pathophysiology (64, 65).

Another promising marker involved in extracellular matrix formation is galectin-3 that plays a role in the progression of atrial fibrosis. It is expressed in fibroblasts, activated macrophages, neutrophils and mast cells and participates in several processes involved in fibrogenesis. In AF, elevated levels of galectin-3 correlate with advanced disease and worse outcomes (66). Notably, galectin-3 levels are increased in serum of COVID-19 patients and correlates with COVID-19 severity (67, 68). Increased levels of aldosterone, another key player in adverse myocardial remodeling, are also found (67). A distinctive hallmark of SARS-CoV-2 infection is systemic immune cell over-activation, with an imbalance between T–helper–1 (Th1) and Th2 cells, elevated levels of IL-1β, IL-2, IL-6, IL-7, interferons, TNF-α, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1A among others (69–72). At the cardiac level, pro-inflammatory cytokines, in particular IL-6, stimulates vascular smooth muscle proliferation, endothelial cell and platelets activation, and leads to apoptosis or necrosis of myocardial cells, which may mediate intra-atrial repolarization and conduction disturbances (73). Raised levels of IL-6 in COVID-19 deaths suggest that virus-driven hyper-inflammation is strictly correlated to and increased susceptibility to lethal arrhythmia (74). SARS-CoV-2, through its binding to ACE2, purinergic receptors and components of the complement-mediated pathway, also stimulates the formation of the Nod-like receptor pyrin domains-containing 3 (NLRP3) inflammasome (75, 76). The NLRP3 inflammasome, in turn, triggers an immune response that leads to a further release of pro-inflammatory cytokines, inflammatory cell death, and Ang II-mediated tissue remodeling (77). There is a causal link between activation of the NLRP3 inflammasome in atrial cardiomyocytes and AF development. The mechanisms underlying the pro-arrhythmic effects of NLRP3 inflammasome take account of abnormal diastolic RyR2-mediated sarcoplasmic reticulum Ca²⁺ release with generation of pro-arrhythmic delayed afterdepolarizations (DADs), continued activation of ultra-rapid delayed rectifier K⁺ current with action potential abbreviation, and atrial hypertrophy and fibrosis (27, 38, 78).

Another relevant pathophysiological component in patients with severe COVID-19 is endothelial dysfunction that may be related, in addition and in combination to cytokine network, to progression and worsening of AF episodes (79–81). The mechanisms are various and not completely understood. It has been hypothesized that a downregulation of ACE2 activates the kallikrein-bradykinin system, increasing vascular permeability to immune cells, which upon activated, produce reactive oxygen species, cytokine and vasoactive molecules release, which lead to endothelial cell dysfunction and loss (82, 83). Impairment of endothelium compartment by SARS-CoV-2, by amplifying the expression of pro-coagulative molecules (i.e., tissue factor) and reducing the level of endothelial antithrombotic molecules, may be responsible for an enhancement of the coagulation cascade (84).

Lastly, in COVID-19 as well as in other viral infection, the activation of sympathetic nervous system takes place (85, 86). The mechanisms linking the increase in the sympathetic tone to AF episodes can involve increase in Ca²⁺ influx and overload in cardiomyocytes. This elevates the frequency of spontaneous diastolic Ca²⁺ release via RyR with subsequent generation of DADs and action potentials, which increase the probability of AF events (87).

Overall, there are several common pathophysiological points between COVID-19 and AF, and a potential mechanistic link emerges as a valid working hypothesis. Additionally, pre-existing genetic background consisting of ion-channel and gap junctional protein abnormalities may form the molecular substrate that favors the abnormal conduction properties and electrical activity in the atrial myocardium.

2.3. AF management in COVID-19 patients

Deregulation of the coagulation system and the risk of thromboembolism are highly relevant for both AF and COVID-19. Pre-existing antithrombotic therapy may be associated with lower odds of COVID-19 death (88, 89). Although no specific therapy has been recommended, anticoagulant therapy is required. Systemic anticoagulants have been reported to reduce mortality in hospitalized patients with COVID-19 and symptoms of coagulation disorders (90). The use of non-vitamin K antagonist oral anticoagulants (NOACs) in hospitalized COVID-19 patients with AF is a therapeutic alternative (91).

However, clinical findings have demonstrated relevant interactions between COVID-19 drugs and anticoagulants. In particular, lopinavir/ritonavir, via cytochrome P450 CYP3A4, may increase the bleeding risk, and NOACs should be avoided (92). As heparins are not expected to interact, they may be considered a safe option. In addition to the antithrombotic effect, heparin anti-inflammatory actions are relevant in this setting (93).

There are few data on the efficacy of rhythm and rate control in patients with AF and COVID-19, and combination therapy with antiarrhythmics and anticoagulants is associated with substantial side effects (94). Cardioversion should be considered in patients with hemodynamic instability, and intravenous amiodarone is the antiarrhythmic drug of choice for rhythm control (95). Rate control may be achieved by intravenous diltiazem (96). In stable patients on antiviral treatment, the interruption of antiarrhythmic drugs is preferable while the initiation of rate control therapy with β-blockers or non-dihydropyridine calcium channel blockers allows the use of antiviral drugs without risk of prolongation of the QT interval (97). Generally, drug-drug interactions should be considered before starting therapy.

To date, it is not clear if AF events experienced by COVID-19 patients are transitory phenomena or they progress into permanent AF. Nonetheless, it remains critical to direct a strict focus to adverse effects of COVID-19 and plan specific screening for irregular heartbeats. To avoid complications, an accurate diagnosis of AF is crucial and remains a major challenge.

A randomized trial recruiting more than 1,000 patients with confirmed COVID-19 has demonstrated that therapeutic-dose anticoagulation does not affect the probability of survival to hospital discharge (98). Therefore, assessing the risk for anticoagulation measures by lowering therapeutic-dose anticoagulation in COVID-19 patients at high risk of AF is a strategy that is worth investigating, although it must be taken into account that AF, without adequate treatment, leads to serious complications.

2.4. Risk of drug-related cardiac arrhythmias during COVID-19 therapy

Pharmacological agents commonly used in COVID-19 patients may have a risk of inducing electrophysiological changes and severe and potentially fatal cardiac dysfunction, such as torsades de pointes, ventricular tachycardia and fibrillation (99). Furthermore, patients with underlying heart disease such as inherited arrhythmia syndromes (long QT or Brugada syndromes) are predisposed to an increased risk of cardiac arrhythmias (100). The sum of pharmacotherapy and hereditary factors represents a hazardous combination of pro-arrhythmogenic effects. The use of lopinavir/ritonavir combination has been associated with and increased QT prolongation through a multichannel blocking properties (101). Ibrutinib, the first human Bruton’s tyrosine kinase inhibitor (TKI), has been largely studied in hospitalized COVID-19 patients due to its potential to lessen lung inflammation and injury (102, 103). However, clinical data have revealed an increased risk of atrial and ventricular arrhythmias, sinoatrial arrest, and heart failure; therefore, patients on ibrutinib therapy must be carefully monitored (104). The postulated mechanism seems to be a disrupted Ca²⁺ handling in the myocardium, favoring DADs. Other TKIs exert in vitro inhibitory activity against SARS-CoV-2 (105), although patients treated with TKIs have experienced cardiac toxicity (106). This pro-arrhytmogenic effect may be related to a modulation of ionic channels (decreasing K⁺ current amplitude, and interfering with Na⁺ and Ca²⁺ currents).

Remdesivir is an antiviral drugs initially used in patients infected by Ebola virus, and authorized for treatment of COVID-19 disease in hospitalized patients (107). Few studies on remdesivir have pointed out its adverse effects on the cardiovascular system. COVID-19 patients with an oxygen saturation of less than 94% receiving intravenous remdesivir have experienced AF and adverse events are more prevalent in patients undergoing invasive ventilation. However, the interpretation is inconclusive due to small sample size, short follow-up and absence of a control group (108). In another study, elevated plasma concentration of remdesivir following intravenous administration significantly increased the risk of QT prolongation and torsades de pointes (109). The analysis of EudraVigilance database has revealed a two-fold increased risk of an adverse cardiac event associated with remdesivir in comparison with hydroxychloroquine and azithromycin. Cardiac arrhythmias are the most reported events (110). Additional evidence has shown that remdesivir, for its chemical structure of adenosine nucleotide analog and pharmacological profile, may act as a blocker of the atrioventricular node and be pro-arrhythmic especially in patients with structural heart disease (111). Thus, the use of other drugs and a pre-existing risk have to be considered to establish cardiovascular risk for patients with COVID-19 qualified for remdesivir treatment.

3. Conclusion

Although most of the symptoms in COVID-19 patients involve the respiratory system, a significant fraction of patients presents serious cardiovascular complications. Arrhythmias are one of the main cardiac manifestations of COVID-19 with AF being the most common form of arrhythmia in these patients. While the pathophysiology underlying AF onset in COVID-19 patients are incompletely understood, from the clinical and basic research emerges an array of common mechanisms in the onset of AF and COVID-19 development. A direct viral invasion of myocardial cells, systemic inflammation with the release of inflammatory cytokines and pro-fibrotic mediators, along with changes in ion channel physiology and local RAAS, have been noted.

Pharmacological agents commonly used in COVID-19 patients may carry a risk of inducing electrophysiological changes and the management of arrhythmias should be based on evidence-based guidelines, with consideration of severity of COVID-19, the nature of AF and the concomitant use of antimicrobial and anti-inflammatory drugs. Finally, “off label” or “new” drugs used in acute COVID-19, vaccines with favorable efficacy and safety profile, and residual risk related to the “long COVID syndrome,” need attention also in the context of arrhythmic manifestations.

Author contributions

MD, KU, FR, and DC: conceptualization and writing. MD, CR, EC, and DC: literature collection and visualization. AD, PP, DT, GS, GP, GC, KU, LB, and DC: review and editing. All authors contributed to the article and approved the submitted version.

Funding Statement

This review was supported by the Italian Ministry of Education, the University and Research grants [PRIN-2017XZMBYX (AD) and PRIN-2017NKB2N4 (LB)].

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.